Clinical characteristics and management of ALS

被引:63
作者
Borasio, GD [1 ]
Miller, RG
机构
[1] Univ Munich, Klinikum Grosshadern, Dept Neurol, D-81366 Munich, Germany
[2] Univ Munich, Interidsciplinary Palliat Care Unit, D-81366 Munich, Germany
[3] Calif Pacific Med Ctr, Dept Neurol, San Francisco, CA USA
[4] Calif Pacific Med Ctr, Forbes Norris MDA ALS Ctr, San Francisco, CA USA
关键词
amyotrophic lateral sclerosis; motor neuron disease; antiglutamatergic agents; symptom control; noninvasive ventilation; palliative care;
D O I
10.1055/s-2001-15268
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Amyotrophic lateral sclerosis (ALS) is the most common form of degenerative motor neuron disease in adulthood, The clinical picture was accurately described by Charcot over 125 years ago and consists of generalized fasciculations, progressive atrophy and weakness of the skeletal muscles, spasticity and pyramidal tract signs, dysarthria, dysphagia, and dyspnea. Pseudobulbar affect is common. Disease-specific treatment options are still unsatisfactory However, therapeutic nihilism is not justified as a large array of palliative measures is available to enhance the quality of life of patients and their families. Palliative care in ALS is a multidisciplinary effort requiring careful coordination. An open and frank disclosure of the diagnosis is of paramount importance. Nutritional deficiency due to pronounced dysphagia can be relieved by a percutaneous endoscopic gastrostomy, Respiratory insufficiency can be effectively treated by noninvasive home mechanical ventilation. The terminal phase of the disease should be discussed, at the latest, when symptoms of dyspnea appear in order to prevent unwarranted fears of "choking to death." Collaboration with hospice and completion of advance directives can be of invaluable help in the terminal phase.
引用
收藏
页码:155 / 166
页数:12
相关论文
共 78 条
[31]   Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familiar amyotrophic lateral sclerosis [J].
Gurney, ME ;
Cutting, FB ;
Zhai, P ;
Doble, A ;
Taylor, CP ;
Andrus, PK ;
Hall, ED .
ANNALS OF NEUROLOGY, 1996, 39 (02) :147-157
[32]   NATURAL-HISTORY OF AMYOTROPHIC-LATERAL-SCLEROSIS IN A DATABASE POPULATION - VALIDATION OF A SCORING SYSTEM AND A MODEL FOR SURVIVAL PREDICTION [J].
HAVERKAMP, LJ ;
APPEL, V ;
APPEL, SH .
BRAIN, 1995, 118 :707-719
[33]   AMYOTROPHIC-LATERAL-SCLEROSIS PATIENTS LIVING BEYOND RESPIRATORY-FAILURE [J].
HAYASHI, H ;
KATO, S ;
KAWADA, A .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1991, 105 (01) :73-78
[34]  
HIRANO A, 1978, AMYOTROPHIC LATERAL, P107
[35]   Pharmacologic treatment of emotional lability [J].
Iannaccone, S ;
FeriniStrambi, L .
CLINICAL NEUROPHARMACOLOGY, 1996, 19 (06) :532-535
[36]  
JANZEN VD, 1988, J OTOLARYNGOL, V17, P41
[37]  
JUERGENS SM, 1980, DIAGNOSIS TREATMENT, P35
[38]   Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis [J].
Klivenyi, P ;
Ferrante, RJ ;
Matthews, RT ;
Bogdanov, MB ;
Klein, AM ;
Andreassen, OA ;
Mueller, G ;
Wermer, M ;
Kaddurah-Daouk, R ;
Beal, MF .
NATURE MEDICINE, 1999, 5 (03) :347-350
[39]   Skin involvement in amyotrophic lateral sclerosis [J].
Kolde, G ;
Bachus, R ;
Ludolph, AC .
LANCET, 1996, 347 (9010) :1226-1227
[40]  
Kondo K, 1995, MOTOR NEURON DIS BIO, P19